Thrombotic Thrombocytopenic Purpura during Interferon Alpha Treatment for Chronic Myelogenous Leukemia
- 1 January 1999
- journal article
- case report
- Published by S. Karger AG in Acta Haematologica
- Vol. 102 (3), 160-162
- https://doi.org/10.1159/000040993
Abstract
Thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome have recently been observed in patients undergoing interferon alpha (IFN-α) therapy. However, the relationship between disease and therapy has not been established, essentially because of concomitant treatment or previous bone marrow transplantation. We present a case of TTP developing during IFN-α therapy for chronic myelogenous leukemia. In this case, IFN-α seems to be the only etiological agent.Keywords
This publication has 5 references indexed in Scilit:
- von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic SyndromeNew England Journal of Medicine, 1998
- Thrombotic Thrombocytopenic Purpura Complicating Chronic Myelogenous Leukemia Treated with Interferon-αActa Haematologica, 1998
- Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1997
- UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic responseThe Lancet, 1995
- Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1994